Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: A prospective evaluation

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Bae, Hyun Mi ^a,b   Lee, Jeong Hoon ^a   Yoon, Jung Hwan ^a   Kim, Yoon J ^a   Heo, Dae S ^a   Lee, Hyo Suk ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Catholic University of Korea   (South Korea)

Author keywords

Hepatocellular carcinoma; Metastases; Predictive marker; Protein induced by vitamin k absence or antagonist ii

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN; PROTEIN INDUCED BY VITAMIN K ABSENCE OF ANTAGONIST II PRODUCTION; TUMOR MARKER; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; PROTEIN PRECURSOR; PROTHROMBIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL OBSERVATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PORTAL VEIN THROMBOSIS; PREDICTION; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RADIOFREQUENCY ABLATION; RISK FACTOR; THROMBOCYTE COUNT; TUMOR VOLUME; BLOOD; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; PROTHROMBIN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80053605097     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-435     Document Type: Article

References (24)

1. Fan ST, Lai EC, Lo CM, Chu KM, Liu CL, Wong J. Hepatectomy with an ultrasonic dissector for hepatocellular carcinoma. Br J Surg 1996, 83:117-20. 10.1002/bjs.1800830138, 8653334.
2. Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, Kawasaki S. Surgery for small liver cancers. Semin Surg Oncol 1993, 9:298-304. 10.1002/ssu.2980090404, 8210909.
3. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-9. 10.1056/NEJM199603143341104, 8594428.
4. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000, 232:381-91. 10.1097/00000658-200009000-00010, 1421151, 10973388.
5. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-71. 10.1053/jhep.2002.33156, 11981766.
6. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003, 37:429-42. 10.1053/jhep.2003.50047, 12540794.
7. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Annals of surgery 2002, 235:373-82. 10.1097/00000658-200203000-00009, 1422443, 11882759.
8. Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Toyoda H, Shimada S, Takahashi M, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology Baltimore, Md 1997, 25:87-92. 10.1002/hep.510250116, 8985270.
9. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nature medicine 2003, 9:416-23. 10.1038/nm843, 12640447.
10. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:4293-300. 10.1200/JCO.2005.01.3441, 16908937.
11. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005, 23:965-72.
12. Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 2008, 112:250-9. 10.1002/cncr.23175, 18041064.
13. Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, Curley SA, Ellis LM, Regimbeau JM, Rashid A, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002, 15;20(6):1527-36.
14. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-38. 10.1055/s-2007-1007122, 10518312.
15. Shimada M, Yonemura Y, Ijichi H, Harada N, Shiotani S, Ninomiya M, Terashi T, Yoshizumi T, Soejima Y, Maehara Y. Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative Protein induced by vitamin K absence or antagonist-II value. Transplant Proc 2005, 37:1177-9. 10.1016/j.transproceed.2004.12.030, 15848661.
16. Shirabe K, Itoh S, Yoshizumi T, Soejima Y, Taketomi A, Aishima S, Maehara Y. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol 2007, 95:235-40. 10.1002/jso.20655, 17323337.
17. Tamano M, Sugaya H, Oguma M, Iijima M, Yoneda M, Murohisa T, Kojima K, Kuniyoshi T, Majima Y, Hashimoto T, et al. Serum and tissue PIVKA-II expression reflect the biological malignant potential of small hepatocellular carcinoma. Hepatol Res 2002, 22:261-9. 10.1016/S1386-6346(01)00150-4, 11929711.
18. Fujikawa T, Shiraha H, Ueda N, Takaoka N, Nakanishi Y, Matsuo N, Tanaka S, Nishina S, Suzuki M, Takaki A, et al. Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J Biol Chem 2007, 282:8741-8. 10.1074/jbc.M609358200, 17255102.
19. Adachi E, Maeda T, Kajiyama K, Kinukawa N, Matsumata T, Sugimachi K, Tsuneyoshi M. Factors correlated with portal venous invasion by hepatocellular carcinoma: univariate and multivariate analyses of 232 resected cases without preoperative treatments. Cancer 1996, 77:2022-31. 10.1002/(SICI)1097-0142(19960515)77:10<2022::AID-CNCR9>3.0.CO;2-S, 8640665.
20. Hagiwara S, Kudo M, Kawasaki T, Nagashima M, Minami Y, Chung H, Fukunaga T, Kitano M, Nakatani T. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J Gastroenterol 2006, 41:1214-9.
21. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, Yoshida H, Shiina S, Omata M. Protein induced by vitamin K absence or antagonist-II as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001, 91:561-9. 10.1002/1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO;2-N, 11169939.
22. Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A, Maeda T. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer 1994, 73:2464-71.
23. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006, 12:410-6. 10.1038/nm1377, 16532004.
24. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y, et al. A decade's studies on metastases of hepatocellular carcinoma. Journal of cancer research and clinical oncology 2004, 130:187-96. 10.1007/s00432-003-0511-1, 14685850.